留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

《中国抗癌协会神经内分泌肿瘤诊治指南(2022年版)》解读

梁贇 吴文铭 聂勇战 陈洁

梁贇, 吴文铭, 聂勇战, 陈洁. 《中国抗癌协会神经内分泌肿瘤诊治指南(2022年版)》解读[J]. 协和医学杂志, 2023, 14(1): 94-100. doi: 10.12290/xhyxzz.2022-0607
引用本文: 梁贇, 吴文铭, 聂勇战, 陈洁. 《中国抗癌协会神经内分泌肿瘤诊治指南(2022年版)》解读[J]. 协和医学杂志, 2023, 14(1): 94-100. doi: 10.12290/xhyxzz.2022-0607
LIANG Yun, WU Wenming, NIE Yongzhan, CHEN Jie. Interpretation on the Chinese Guideline for Diagnosis and Treatment of Neuroendocrine Neoplasms from The China Anti-Cancer Association(2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 94-100. doi: 10.12290/xhyxzz.2022-0607
Citation: LIANG Yun, WU Wenming, NIE Yongzhan, CHEN Jie. Interpretation on the Chinese Guideline for Diagnosis and Treatment of Neuroendocrine Neoplasms from The China Anti-Cancer Association(2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 94-100. doi: 10.12290/xhyxzz.2022-0607

《中国抗癌协会神经内分泌肿瘤诊治指南(2022年版)》解读

doi: 10.12290/xhyxzz.2022-0607
基金项目: 

国家自然科学基金 82141104

详细信息
    通讯作者:

    吴文铭, E-mail:wuwm@pumch.cn

    聂勇战, E-mail:yongznie@fmmu.edu.cn

    陈洁, E-mail:chen0jie@hotmail.com

  • 中图分类号: R730.4; R730.5

Interpretation on the Chinese Guideline for Diagnosis and Treatment of Neuroendocrine Neoplasms from The China Anti-Cancer Association(2022)

Funds: 

National Natural Science Foundation of China 82141104

More Information
  • 摘要: 神经内分泌肿瘤是起源于肽能神经元和神经内分泌细胞的少见肿瘤,具有较高的异质性,临床诊断和治疗复杂。中国抗癌协会神经内分泌肿瘤专业委员会组织相关领域专家,在现有循证医学证据基础上,结合国内外相关指南和共识,制定了首版神经内分泌肿瘤诊治指南。本文旨在对指南的重点内容进行解读,并针对部分争议问题进行讨论,以期为临床实践提供借鉴和参考。
    作者贡献:梁贇负责论文撰写;陈洁、聂勇战、吴文铭负责论文审校和修订。
    利益冲突:所有作者均声明不存在利益冲突
  • [1] Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States[J]. JAMA Oncol, 2017, 3: 1335-1342. doi:  10.1001/jamaoncol.2017.0589
    [2] Fang C, Wang W, Zhang Y, et al. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China[J]. Chin J Cancer, 2017, 36: 51. doi:  10.1186/s40880-017-0218-3
    [3] Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Func-tional Pancreatic Neuroendocrine Tumors[J]. Neuroendocrinology, 2016, 103: 153-171. doi:  10.1159/000443171
    [4] Kamilaris CDC, Stratakis CA. Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis[J]. Front Endocrinol (Lausanne), 2019;10: 339. doi:  10.3389/fendo.2019.00339
    [5] Puliani G, Di Vito V, Feola T, et al. NETest: A Systematic Review Focusing on the Prognostic and Predictive Role[J]. Neuroendocrinology, 2022, 112: 523-536. doi:  10.1159/000518873
    [6] Malczewska A, Kos-Kudła B, Kidd M, et al. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors[J]. Adv Med Sci, 2020, 65: 18-29. doi:  10.1016/j.advms.2019.10.002
    [7] Chen L, Guo Y, Zhang Y, et al. Development of a novel scoring system based on endoscopic appearance for management of rectal neuroendocrine tumors[J]. Endoscopy, 2021, 53: 702-709. doi:  10.1055/a-1274-0161
    [8] Luo Y, Chen J, Huang K, et al. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?[J]. BMC Cancer, 2017, 17: 154. doi:  10.1186/s12885-017-3150-7
    [9] Solis-Hernandez MP, Fernandez Del Valle A, Carmona-Bayonas A, et al. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_GETNE1504 study)[J]. Br J Cancer, 2019, 121: 537-544. doi:  10.1038/s41416-019-0558-7
    [10] Chen L, Wang W, Jin K, et al. Special issue "the advane of solid tumor research in China": Prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors[J]. Int J Cancer, 2023, 152: 90-99. doi:  10.1002/ijc.34294
    [11] Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG[J]. Cancer, 2008, 112: 2447-2455. doi:  10.1002/cncr.23469
    [12] Panagiotidis E, Alshammari A, Michopoulou S, et al. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors[J]. J Nucl Med, 2016, 58: 91-96.
    [13] Rinzivillo M, Partelli S, Prosperi D, et al. Clinical Usefulness of (18)F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms[J]. Oncologist, 2018, 23: 186-192. doi:  10.1634/theoncologist.2017-0278
    [14] Kim YI, Yoo C, Oh SJ, et al. Tumour-to-liver ratio determined by[(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours[J]. EJNMMI Res, 2020, 10: 63. doi:  10.1186/s13550-020-00651-z
    [15] Kuik WJ, Kema IP, Brouwers AH, et al. In vivo biodistribution of no-carrier-added 6-18F-fluoro-3, 4-dihydroxy-L-phenylalanine (18F-DOPA), produced by a new nucleo-philic substitution approach, compared with carrier-added (18F-DOPA), prepared by conventional electrophilic substitution[J]. J Nucl Med, 2015, 56: 106-112. doi:  10.2967/jnumed.114.145730
    [16] Piccardo A, Lopci E, Conte M, et al. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study[J]. Eur J Nucl Med Mol Imaging, 2012, 39: 57-71. doi:  10.1007/s00259-011-1938-2
    [17] Luo Y, Pan Q, Yao S, et al. Glucagon-like Peptide-1 Receptor PET/CT with 68Ga-NOTA-exendin-4 for Detecting Localized Insulinoma: a Prospective Cohort Study[J]. J Nucl Med, 2016, 57: 715-720. doi:  10.2967/jnumed.115.167445
    [18] WHO Classification of Tumours Editorial Board. WHO classification of tumours, 5th Edition, Volume 1: Digestive System Tumours[M]. Lyon: IARC Press, 2019.
    [19] WHO Classification of Tumours Editorial Board. WHO Classification of Tumours, 5th Edition, Volume 5: Thoracic Tumours[M]. Lyon: IARC Press, 2021.
    [20] Travis WD, Brambilla E, Burke AP, et al. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart[J]. J Thorac Oncol, 2015, 10: 1240-1242. doi:  10.1097/JTO.0000000000000663
    [21] Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal[J]. Mod Pathol, 2018, 31: 1770-1786. doi:  10.1038/s41379-018-0110-y
    [22] Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms[J]. Endocr Pathol, 2022, 33: 115-154. doi:  10.1007/s12022-022-09708-2
    [23] Chivukula SV, Tierney JF, Hertl M, et al. Operative resection in early stage pancreatic neuroendocrine tumors in the United States: Are we over-or undertreating patients?[J]. Surgery, 2020, 167: 180-186. doi:  10.1016/j.surg.2019.04.061
    [24] Dong DH, Zhang XF, Poultsides G, et al. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm after curative resection: A multi-institutional study of 392 cases[J]. J Surg Oncol, 2019, 120: 1071-1079. doi:  10.1002/jso.25716
    [25] Lopez-Aguiar AG, Zaidi MY, Beal EW, et al. Defining the role of lymphadenectomy for pancreatic neuroendocrine tumors: An eight-institution study of 695 patients from the US neuroendocrine tumor study group[J]. Ann Surg Oncol, 2019, 26: 2517-2524. doi:  10.1245/s10434-019-07367-y
    [26] Guarneri G, de Mestier L, Landoni L, et al. Prognostic role of examined and positive lymph nodes after distal pancreatectomy for non-functioning neuroendocrine neoplasms[J]. Neuroendocrinology, 2021, 111: 728-738. doi:  10.1159/000509709
    [27] Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors[J]. N Engl J Med, 2014, 371: 224-233. doi:  10.1056/NEJMoa1316158
    [28] Rinke A, Müller HH, Schade-Brittinger C, et al. PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroen-docrine midgut tumors: a report from the PROMID Study Group[J]. J Clin Oncol, 2009, 27: 4656-4663. doi:  10.1200/JCO.2009.22.8510
    [29] Liu Y, Liu H, Chen W, et al. Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden[J]. Cancer Med, 2022, 11: 2588-2600. doi:  10.1002/cam4.4628
    [30] Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?[J]. J Hepatol, 2007, 47: 460-466. doi:  10.1016/j.jhep.2007.07.004
    [31] 中国抗癌协会神经内分泌肿瘤专业委员会. 中国抗癌协会神经内分泌肿瘤诊治指南(2022年版)[J]. 中国癌症杂志, 2022, 32: 545-580. Society of Neuroendocrine Neoplasm of China Anti-Cancer Association. China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasm (2022 edition)[J]. Zhongguo Aizheng Zazhi, 2022, 32: 545-580.
    [32] Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas[J]. Neuroendocrinology, 2016, 103: 186-194. doi:  10.1159/000443172
    [33] National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors (Version 2021)[EB/OL]. [2021-06-18]. https://www.nccn.org/guidelines/guidelines-detail?cate-gory=1&id=1448.
    [34] Bongiovanni A, Liverani C, Foca F, et al. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis[J]. Neuroendocrinology, 2021, 111: 895-906. doi:  10.1159/000513218
    [35] Wang W, Zhang Y, Peng Y, et al. A Ki-67 Index to Predict Treatment Response to the Capecitabine/Temozolo-mide Regimen in Neuroendocrine Neoplasms: A Retrospec-tive Multicenter Study[J]. Neuroendocrinology, 2021, 111: 752-763. doi:  10.1159/000510159
    [36] Apostolidis L, Dal Buono A, Merola E, et al. Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3)[J]. Cancers, 2021, 13: 1936. doi:  10.3390/cancers13081936
    [37] Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer[J]. N Engl J Med, 2018, 379: 2220-2229. doi:  10.1056/NEJMoa1809064
    [38] Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019, 394: 1929-1939. doi:  10.1016/S0140-6736(19)32222-6
  • 加载中
计量
  • 文章访问数:  572
  • HTML全文浏览量:  77
  • PDF下载量:  269
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-10-18
  • 录用日期:  2022-12-05
  • 网络出版日期:  2023-01-16
  • 刊出日期:  2023-01-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!